Dr. Reddy’s Laboratories: Holding on to a Sweet Promise
Dr. Reddy’s has benefitted significantly from gRevlimid sales in the US in the last three years. But that opportunity is now closing by FY26-end. The company has made significant investments...
Dr. Reddy’s has benefitted significantly from gRevlimid sales in the US in the last three years. But that opportunity is now closing by FY26-end. The company has made significant investments...
